The Peptide NewsroomPeptide research, industry and supply-chain headlines

Corexa Logs First Compounded Peptide Sale, But the FDA Has Not Approved These Drugs

By The Peptide Newsroom Desk · Date: 0views 0comments
Topic card: fda

DataMEDS AI announced on November 9 that its Corexa Pharmacy subsidiary completed its first commercial sale of a compounded peptide under the Department of Health and Human Services' Enforcement Discretion Policy. The company states plainly in the same release that these compounded drugs are not FDA-approved and have not been evaluated by the agency for safety or efficacy.

The peptide sold is one of six named by the FDA's Pharmacy Compounding Advisory Committee at its July 23 and 24, 2026 meeting: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. Compounded drugs are mixed by a pharmacy for an individual patient rather than manufactured and approved as a standard product, which is why they sit outside the approval pathway most people assume applies to anything sold by a pharmacy.

What enforcement discretion actually means

Enforcement discretion is not approval. It is a policy position describing what the agency is choosing not to pursue, and the company's own forward-looking statements flag the possibility that the FDA or HHS may change or withdraw it, along with the agency's pending final decisions on the 503A bulks list.

That is an unusually candid risk disclosure for a press release, and it is the part of this story worth holding onto. The business being built here rests on a policy that the company itself describes as revocable.

The commercial read

Corexa says it is still working through its pricing model and intends to begin marketing soon, aimed at prescribing physicians rather than consumers, since compounded medications are prescribed one patient at a time. Interim Co-CEO Gerald Commissiong framed the first sale as confirmation that the pharmacy can dispense the six peptides in compliance with the new guidelines.

The market context cited is Precedence Research's estimate that U.S. compounding will grow from $18.02 billion in 2025 to over $31.77 billion by 2034. That is the whole compounding market, not the peptide slice of it, and nothing in the release breaks out what share these six compounds might represent.

Bottom line

This is a regulatory and logistics milestone, not a clinical one. No safety or efficacy data accompanies the announcement, because under enforcement discretion none is required, and that gap is the thing physicians will be asked to bridge with their own judgment.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: fda, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

J&J Says Oral Peptide Icotrokinra Beat Placebo in Psoriatic Arthritis, But Approval Is Not There Yet

Johnson & Johnson reported Phase 3 results for the oral peptide icotrokinra in psoriatic arthritis, with 58% of patients reaching an ACR20 response at Week 16 against 41% on placebo. The data come from a conference poster, the drug is not approved for the condition, and the later figures have no placebo comparator.

HHS Draft Policy Names MOTS-c, But the Peptide Is Still Not FDA-Approved

A California clinic's press release highlights MOTS-c's inclusion in a draft HHS enforcement-discretion policy for 503A peptide compounding, published October 30, 2026. The framework covers six peptides and explicitly does not make any of them FDA-approved.

RFK Jr. Eases Access to Unproven Peptides, But FDA Scientists Pushed Back Hard

A draft HHS policy would ease access to a handful of injectable peptides marketed for muscle, injury recovery and energy, over opposition from FDA scientific staff. A UNLV hematologist laid out the timeline and the risks on local television as a two-week comment window opened.